All News

A randomized clinical trial published by JAMA Internal Medicine found that the distribution of HIV self-tests is a useful source for increasing awareness of HIV infection, and for preventing future transmission, specifically among men having sex with men.

Why is a woman being prescribed phentermine for ADHD?

Each November, members of the chronic obstructive pulmonary disease (COPD) community come together to focus on increasing awareness of the respiratory condition.

Approved by the FDA in May 2019, midazolam nasal spray CIV (Nayzilam, UCB) is the first nasal rescue treatment for seizure clusters in the United States.

Top news of the day from across the health care landscape.

The case study included a 45-year-old man diagnosed with stage 3 multiple myeloma who was treated with bortezomib and dexamethasone.

If approved, risdiplam (Genentech) would be the first at-home administered medicine for patients living with spinal muscular atrophy.

Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss how pharmacy schools can better prepare students for Specialty Pharmacy during the NASP Annual Meeting in Washington, DC.

The study evaluated the safety and efficacy of a live, attenuated zoster vaccine patients receiving tumor necrosis factor inhibitor therapies for various indications.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Top news of the week from Specialty Pharmacy Times.

Consulting with some pharmacist moms and colleagues, these are the top tips for how they make the holidays more of a celebration and less of a logistical nightmare.

Top news of the day from across the health care landscape.

A patient at age 65 with high blood pressure could extend their life by more than a year with intensive treatment focused on a target systolic blood pressure of less than 120 mm Hg.

The FDA has approved cenobamate tablets (XCOPRI, SK Life Sciences) for treatment of partial-onset seizures in adults.

Under a new international collaboration, the FDA has granted supplemental approval to acalabrutinib (Calquence, AstraZeneca) for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic leukemia.

Tafenoquine’s approval was the culmination of years of scientific discovery and research by experts in the field of Malariology and Infectious Disease, involving over 25 clinical trials and over 3000 participants.

A team of researchers from Columbia University, New York City compared the incidence of chlamydia infection in adolescent LARC users to non-LARC users.